Summit Therapeutics Inc. announced on March 17, 2025, the appointment of Robert LaCaze as its new Chief Commercial Officer, effective immediately. Mr. LaCaze brings over 35 years of executive leadership experience in the biopharmaceutical industry, with a focus on oncology commercial strategy and execution.
His previous roles include Executive Vice President and Head of the Oncology Strategic Business Unit at Bayer Healthcare and Senior Vice President and Head of Global Oncology at Bristol-Myers Squibb. This extensive background includes launching multi-billion-dollar products and building blockbuster drug franchises.
The appointment of Mr. LaCaze is a strategic step for Summit as it prepares for the potential commercial launch of ivonescimab. His expertise is expected to be instrumental in driving the company's commercial efforts and expanding market presence for its innovative oncology therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.